GSK Appoints Tony Wood as CSO
On Wednesday, January 19, GSK announced (press release) the appointment of Tony Wood as Chief Scientific Officer (CSO), effective August 1, 2022. Of note, Hal Barron will step down as GSK’s CSO and become a Non-Executive Director of the Board, with additional responsibilities to support R&D. Furthermore, Barron will become CEO and Board Co-Chair of Altos Labs effective August 1, 2022. Below, Celltelligence provides insights on how Wood’s appointment may impact GSK’s development of innovative therapies.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.